E057 A systematic review of new rheumatic immune-mediated inflammatory diseases (R-IMID) following SARS-CoV-2 vaccinations

Abstract Background/Aims There are sporadic reports about the development of new rheumatic immune-mediated inflammatory diseases (R-IMIDs) in adults after receiving SARS-CoV-2 vaccines. This systematic review (SR) aimed to critically and summarize clinical profile, patient demographics, treatment, prognosis new-onset R-IMIDs following vaccination. Methods We retrieved English-language articles (Case series observational studies) on vaccination, published until June 2022, from standard databases (MEDLINE, Embase, Cochrane). The search strings used during literature incorporated ‘SARS-CoV-2 vaccination’ (along with related MeSH terms) various key terms for [which included (but was not limited to) arthritis, connective tissue disease (CTD), vasculitis, systemic lupus erythematosus, Sjogren’s syndrome, sarcoidosis, sclerosis, idiopathic myositis, anti-synthetase Adult-onset Stills (AOSD), giant cell arteritis (GCA), polymyalgia rheumatica (PMR)]. protocol registered PROSPERO (CRD42022318561). Results Of total 2179 retrieved, 1986 were excluded title-abstract screening, 107 that did meet inclusion criteria. remaining 86 (130 cases) upon full-text screening. Furthermore, we added four (six based a manual search, comprising 90 (136 final analysis. These 136 R-IMID cases reported 27 different countries. these, more than one-third three countries (viz., Italy, Japan, USA). patients had mean age 57 (range:17-90) years, majority females (63.0%). Most developed Pfizer-BioNTech vaccine (76; 55%), followed by Oxford AstraZeneca (35; 25%). duration between vaccination 9.2 (range:1-90) days. second dose resulted (74;54%) first (53;39%). CTDs (34; 25%) small vessel vasculitis (33; 24%) commonest manifestations, arthritis AOSD, each 13 (9.5%) cases. Nearly half Idiopathic Inflammatory Myositis. PMR GCA accounted 16 (11.7%) 5 (3.6%) cases, respectively. However, no axial spondylarthritis reported. (118; 86%) treated corticosteroids, number steroid-sparing drugs, such as methotrexate, rituximab cyclophosphamide. (125; 91%) went into either remission or improvement treatment. Only admitted intensive care unit (ICU) manage their disease; One them died due fatal myositis rhabdomyolysis; two surviving ICU ANCA-associated lung involvement. Conclusion Although rare, this SR highlights emergence de novo cannot confirm causality onset R-IMID. further research is warranted area. Disclosure A. Nune: None. K. Bora: K.P. Iyengar: B. Barman: V. Durkowski: S. Venkatachalam: Bilgrami: L. Ottewell: C. Manzo: